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 Supplementary Figure 1. Evaluation of tumor growth and proliferation index into sc glioma  
 
 
A. Representative images of sc tumor mass in different group of treatment (a: GL261; b: nTh17; c: TGF-nTh17; d: 
gTh17; e: TGF-gTh17). Tumors derived from sc injection were excised 20 days later and measured. The highest tumor 
growth inhibition was observed in the group of nTh17 treated mice compared to the other groups: GL261-cells only 
34±39.5mm3 vs 235.3±22.0 mm3 respectively, (p=0.003); TGF-nTh17 and gTh17 (p<0.02); TGF-gTh17 (p=0.003). Co-
injection with TGF-nTh17 or gTh17 promoted tumor growth and glioma volumes were 405±134.5 mm3 (p=0.02 vs 
GL261; p=0.01 vs nTh17) and 341±128.7 mm3 (p=0.02 vs GL261; p=0.01 vs nTh17 ), respectively. Increased tumor 
growth was found in gliomas from mice co-injected with TGF-gTh17 (866±627 mm3, p=0.01 vs GL261, p<0.001 vs 
nTh17, p<0.04 vs TGF-nTh17 and gTh17). B. Quantitative analysis of the number of Ki67 positive tumor cells. Data are 
expressed as mean values ± SD and are representative for three tumors for each group (** p<10-6, *** p<10-8vs nTh17).  
C-G. Tumors derived from injection of GL261 cells are poorly proliferative and (40,36±2,7) % of tumor cells express 
Ki67 antigen. The most significant difference in proliferating index was observed in nTh17 (24,77±1,12 % Ki67+ cells) 
and TGF-gTh17 (92,13±2,18%). These data correlate with the analysis of relative tumor size. 
Supplementary Fig. 2. Characterization of tumor microenvironment in sc gliomas 
 
A, C. In nTh17 we found enhanced expression of IFN-γ (28.2 folds vs TGF-gTh17 tumors; p<0.0001) and TNF-α (3.3 
fold higher, p<0.001). B, D. On the contrary IL-10 and TGF-β strongly increased in TGF-gTh17. In particular, TGF-β 6.5 
fold higher than sc nTh17 gliomas (p<0.0001). IL-10 25.6 fold higher (p<0.0001). E, F. CD4+ and Foxp3+ cells are 
detected in each sc experimental group within the tumor mass (left columns) and at the periphery (right columns). CD4+ 
TIL are relevant in all groups and located at tumor periphery with exception of TGF-nTh17 where CD4+ cells were 
preferentially distributed into the tumor mass. Foxp3+ cells appeared lower in nTh17-tumors preferentially located at 
tumor borders in all groups. In the centre of the tumor CD4+ lymphocytes are dispersed as single cells, except in TGF-
nTh17 group where they were localized as clusters near tumor vessels. Most lymphocytes are concentrated at the 
interface of the tumor mass suggesting their recruitment from the periphery. There were no significant differences in 
CD4+ infiltrate for each experimental groups. We observed a similar distribution of Foxp3+ cells: large number of these 
cells were found mainly at the tumor edge. The infiltration of CD8+ cells was absent in all tumors, rare positive cells 
were revealed near the periphery vessels but not into the tumor mass (data not shown).  
Sequences of target genes for SYBR-GREEN Chemistry: 
b2m: F 5’-CACTGACCGGCCTGTATGCT-3’R 5’-AGGCGGGTGGAACTGTGTTA-3’ 
TGF-β: F 5’-CTAATGGTGGACCGCAACAAC-3’ R 5’- GCACTGCTTCCCGAATGTCT-3’ 
IL-10: F 5’-CAGAGCCACATGCTCCTAGA -3’ R 5’-GTCCAGCTGGTCCTTTGTTT-3’ 
IL-17R: F 5’-TGGCCAGGAGTATGAAGTGACTG-3’ R 5’-ATCTTCATCTTGCTGTCCTGACAG-3’ 
TNF-α: F 5’-GCCACCACGCTCTTCTGTCTA-3’ R 5’-TGAGGGTCTGGGCCATAGAA-3’ 
Assays of target genes for TaqMan® Chemistry: 
b2m: Mm00437762_m1, IFN-γ: Mm01168134_m1, IL-17A: Mm00439619_m1, Foxp3: Mm00475162_m1
Supplementary Fig. 3. In vitro evaluation of IL-17A effects on GL261- cells proliferation 
 
A. Detection of IL-17 receptor (IL-17R) in GL261 cells was evaluated by a semi-quantitative PCR. GL261 cells express 
IL-17R compared with the positive controls naïve and gl-splenocytes. B. Proliferation Kinetic assay: to analyze the effect 
of IL-17 on GL261 proliferation in vitro, 2x105 cells/flask were cultured in vitro for 18 days at different concentration of 
IL-17 and counted every six days. Cells number is reported as LOG (cell num/10000) and growth medium was used as 
negative control. Different concentration of IL-17 induce no significant change in the GL261 cells proliferation kinetic 
compared with negative control. C. MTT Assay (Millipore, USA) was used for quantification of GL261 proliferation 
using the protocol suggested by the manufacturer. Growth medium was used as blank. A standard curve was defined 
considering the absorbance in the MTT test (570-630 nm) and the number of cells and relative data were reported as 
histograms. GL261 cells were plated on 96-well flat-bottomed at a density of 5x105 cells per well and cultured for 4, 24 
and 48 hours at different concentration of IL-17. Values are mean results from triplicate cultures and are representative of 
three independent experiments. For each experimental condition, IL-17 has no effects in vitro on GL261 cells growth. 
Supplementary Figure 4. TGF-β production by GL261 cells and the effect on RORγt and T-bet expression. 
 
 
A, B. Total mRNA was isolated from GL261 cells and from GL261 gliomas explanted at two different time points (15 
and 25 days after tumor implantation). The relative levels of each RNA was calculated by the 2-∆∆CT method with beta-2-
microglobulin as housekeeping gene control. Both TGF-β1 and TGF-β2 isoforms are expressed at higher levels by 
GL261-glioma compared to cultured cells (p=0.001). Gliomas explanted on day 25 day expressed higher level of both 
isoforms than gliomas explanted on day 15 after implantation (* p=0.01; ** p=0.001 cells and glioma day 15 vs glioma 
day 25). Data are representative of three different experiments. C, D. Production of TGF-β was measured by ELISA 
(R&D Systems, Minneapolis MN), in cell culture supernatant and in extracts obtained from GL261 cells and from 
intracranial gliomas. GL261-cells and explanted GL261-gliomas were homogenized in isotonic buffer. TGF-β levels were 
normalized to total protein content determined by MICROBCA assay (Pierce, Thermo Scientific, Rockford, IL). The data 
are expressed as pg/mg total protein and show mean ± SD of three independent evaluations. 
Increasing TGF-β1 and TGF-β2 protein is prominent in extract obtained directly from explanted glioma (* p=0.01; ** 
p=0.001 supernatant and cell extract vs glioma extract) showing that the production of TGF-β isoforms increases in vivo. 
E, F. Both in vitro and ex vivo isolated cells express the transcription factor RORγt. T-bet expression in in vitro nTh17 
and TGF-nTh17 cells was very low but detectable. When we evaluated ex vivo IL-17+ cells obtained from gliomas on day 
20, we found increased expression of T-bet in Th17 cells from gliomas derived from co-injection with nTh17, supporting 
an in vivo generation of Th1/Th17 cells. IL-17+ cells from TGF-nTh17 gliomas showed decreased T-bet expression 
compared to nTh17 not exposed to TGF-β (*** p=0.0002). 
 Supplementary Table 1. Flow cytometry analysis of positive and negative fraction obtained from splenocytes  
 
Positive 
fraction 
(68.0±1.5%) 
CD3/CD4 
% 
CD4/CD25/Foxp3 
%  
CD3/CD8 
% 
n-splenocytes 71.6±14.8 0.5±0.3 3.3±1.6 
TGF-n- 
splenocytes 82.8±3.9 0.4±0.1 3.5±0.1 
gl-splenocytes 68.5±3.5 0.8±0.3 3.7±0.7 
TGF- gl 
splenocytes 69.5±12.0 0.1±0.09 3.0±1.2 
Mean±SD 73.1±6.6 0.4±0.3 3.4±0.3 
Negative 
Fraction 
CD3/CD4 
% 
CD4/CD25/Foxp3 
%  
CD3/CD8  
% 
n-splenocytes 11.2±4.8 6.2±1.2 9.3±1.9 
TGF-n- 
splenocytes 17.7±3.3 12.6±2.7 7.4±2.6 
gl-splenocytes 15.3±2.4 19.0±3.5 5.3±1.1 
TGF-gl 
splenocytes 5.7±2.3 25.3±2.4 4.8±3.3 
Mean±SD 12.5±5.3 15.8±8.2 6.7±2.1 
T-test 
positive vs negative 
fraction 
CD3/CD4 
% 
CD4/CD25/Foxp3 
%  
CD3/CD8 
% 
<0.00001 0.003 0.02 
 
 
IL-17 positive fraction is mostly enriched for CD3/CD4 + T cells (p<0.00001), depleted for CD4+ CD25+ Foxp3+ cells 
(p= 0.003) and for CD3/CD8+ T cells (p=0.02). p value was obtained comparing the positive fraction versus negative 
fraction. Data are presented as mean values ± SD obtained combining percentage obtained at two different time points of 
splenocyte pre-stimulation (24 and 48 hours). 
